25 Sep 2025 | 5 Mins Read
Ipca to License Cancer, Autoimmune Drug to US Firm BSS
Flipitmoney
Ipca Laboratories Ltd signed a technology transfer and joint development agreement with BioSimilar Sciences PR LLC for a next-generation monoclonal antibody biosimilar targeting cancer and autoimmune diseases. The agreement will transfer development and manufacturing to BSS' Puerto Rico campus, with BSS receiving exclusive US/Canada rights. First biosimilar launch planned for 2027.